Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 76Squamous Cell Carcinoma of Head and Neck 43Lung Neoplasms 34Urinary Bladder Neoplasms 22Oropharyngeal Neoplasms 22Head and Neck Neoplasms 18Nasopharyngeal Carcinoma 17Carcinoma 15Biliary Tract Neoplasms 15Small Cell Lung Carcinoma 14Uterine Cervical Neoplasms 13Parkinson Disease 4, Autosomal Dominant Lewy Body 13Neoplasm Metastasis 13Esophageal Squamous Cell Carcinoma 13Cholangiocarcinoma 13Colorectal Neoplasms 12Pancreatic Neoplasms 11Neoplasms 11Carcinoma, Squamous Cell 11Ovarian Neoplasms 10Mouth Neoplasms 9Laryngeal Neoplasms 9Gallbladder Neoplasms 8Endometrial Neoplasms 8Carcinoma, Transitional Cell 8Hypopharyngeal Neoplasms 7Esophageal Neoplasms 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Mesothelioma, Malignant 6

Interventions

cemiplimab 1Pemetrexed 1Paclitaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Non-small Cell Lung Cancer × Cisplatin × 90 days × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡